AV0328, one of Alopexx’s lead candidates, is a synthetic PNAG vaccine that has completed a phase 1 trial. The biotech is ...

Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best (PKB) ...

The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...

Quest Diagnostics will take over the kidney-focused lab testing portfolio of the dialysis giant Fresenius Medical ...

Eikon Therapeutics is no stranger to eye-popping funding rounds, and the cancer-focused biotech has continued this trend with ...

Idorsia, which is no stranger to needing to find cash quickly, also said it has raised 150 million Swiss francs ($167 million ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

With Lava Therapeutics still smoldering from the decision to dump its lead blood cancer drug, the biotech is now laying off ...